Suppr超能文献

相似文献

1
A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.
Biochem Pharmacol. 2018 Dec;158:298-304. doi: 10.1016/j.bcp.2018.10.035. Epub 2018 Nov 2.
2
A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.
Biochem Pharmacol. 2019 Dec;170:113668. doi: 10.1016/j.bcp.2019.113668. Epub 2019 Oct 16.
3
Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes.
Chem Biol. 2014 Aug 14;21(8):945-54. doi: 10.1016/j.chembiol.2014.06.006. Epub 2014 Jul 24.
4
Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.
J Med Chem. 2017 Mar 23;60(6):2373-2382. doi: 10.1021/acs.jmedchem.6b00965. Epub 2017 Mar 1.
5
Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.
Cell Mol Life Sci. 2017 Dec;74(23):4353-4367. doi: 10.1007/s00018-017-2583-0. Epub 2017 Jul 1.
6
The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.
FASEB J. 2017 Nov;31(11):4697-4706. doi: 10.1096/fj.201601370RR. Epub 2017 Jul 13.
8
Structure-Activity Relationships of Butyrophilin 3 Ligands.
ChemMedChem. 2020 Jun 17;15(12):1030-1039. doi: 10.1002/cmdc.202000198. Epub 2020 May 26.
9
Synthesis and evaluation of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate analogs as competitive partial agonists of butyrophilin 3A1.
Eur J Med Chem. 2024 Oct 5;276:116673. doi: 10.1016/j.ejmech.2024.116673. Epub 2024 Jul 14.
10
Diester Prodrugs of a Phosphonate Butyrophilin Ligand Display Improved Cell Potency, Plasma Stability, and Payload Internalization.
J Med Chem. 2023 Nov 23;66(22):15309-15325. doi: 10.1021/acs.jmedchem.3c01358. Epub 2023 Nov 7.

引用本文的文献

1
Synthesis and evaluation of triazole-containing aryl/acyloxy prodrugs of a BTN3A1 ligand.
Eur J Med Chem. 2025 Apr 5;287:117345. doi: 10.1016/j.ejmech.2025.117345. Epub 2025 Feb 1.
2
Enhanced Plasma Stability and Potency of Aryl/Acyloxy Prodrugs of a BTN3A1 Ligand.
ACS Med Chem Lett. 2024 Sep 25;15(10):1771-1777. doi: 10.1021/acsmedchemlett.4c00371. eCollection 2024 Oct 10.
3
Synthesis and evaluation of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate analogs as competitive partial agonists of butyrophilin 3A1.
Eur J Med Chem. 2024 Oct 5;276:116673. doi: 10.1016/j.ejmech.2024.116673. Epub 2024 Jul 14.
4
Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy.
Clin Transl Immunology. 2024 Feb 19;13(2):e1492. doi: 10.1002/cti2.1492. eCollection 2024.
5
Diester Prodrugs of a Phosphonate Butyrophilin Ligand Display Improved Cell Potency, Plasma Stability, and Payload Internalization.
J Med Chem. 2023 Nov 23;66(22):15309-15325. doi: 10.1021/acs.jmedchem.3c01358. Epub 2023 Nov 7.
6
Hydroxy- and Amino-Phosphonates and -Bisphosphonates: Synthetic Methods and Their Biological Applications.
Front Chem. 2022 Jun 1;10:890696. doi: 10.3389/fchem.2022.890696. eCollection 2022.
7
Generation of effector Vγ9Vδ2 T cells and evaluation of their response to phosphoantigen-loaded cells.
STAR Protoc. 2022 Jun 4;3(2):101422. doi: 10.1016/j.xpro.2022.101422. eCollection 2022 Jun 17.
8
Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions.
RSC Med Chem. 2022 Mar 1;13(4):375-391. doi: 10.1039/d1md00297j. eCollection 2022 Apr 20.
9
Efficiency of bis-amidate phosphonate prodrugs.
Bioorg Med Chem Lett. 2022 Jun 15;66:128724. doi: 10.1016/j.bmcl.2022.128724. Epub 2022 Apr 8.
10
Synthesis and Metabolism of BTN3A1 Ligands: Studies on Diene Modifications to the Phosphoantigen Scaffold.
ACS Med Chem Lett. 2022 Jan 27;13(2):164-170. doi: 10.1021/acsmedchemlett.1c00408. eCollection 2022 Feb 10.

本文引用的文献

1
Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.
J Med Chem. 2018 Oct 11;61(19):8658-8669. doi: 10.1021/acs.jmedchem.8b00655. Epub 2018 Sep 26.
2
Human γδ T-Cell Control of Mucosal Immunity and Inflammation.
Front Immunol. 2018 May 7;9:985. doi: 10.3389/fimmu.2018.00985. eCollection 2018.
3
Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells.
Front Immunol. 2018 Apr 20;9:828. doi: 10.3389/fimmu.2018.00828. eCollection 2018.
4
Butyrophilin3A proteins and Vγ9Vδ2 T cell activation.
Semin Cell Dev Biol. 2018 Dec;84:65-74. doi: 10.1016/j.semcdb.2018.02.007. Epub 2018 Mar 9.
5
Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand.
ACS Med Chem Lett. 2017 Aug 9;8(9):914-918. doi: 10.1021/acsmedchemlett.7b00245. eCollection 2017 Sep 14.
6
BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.
ACS Chem Biol. 2017 Oct 20;12(10):2631-2643. doi: 10.1021/acschembio.7b00694. Epub 2017 Sep 14.
7
The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.
FASEB J. 2017 Nov;31(11):4697-4706. doi: 10.1096/fj.201601370RR. Epub 2017 Jul 13.
8
Adoptive Transfer of Phosphoantigen-Specific γδ T Cell Subset Attenuates Infection in Nonhuman Primates.
J Immunol. 2017 Jun 15;198(12):4753-4763. doi: 10.4049/jimmunol.1602019. Epub 2017 May 19.
10
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
J Immunother Cancer. 2017 Feb 21;5:9. doi: 10.1186/s40425-017-0209-6. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验